Anthem Biosciences Share Price Target 2026: Shares of Anthem Biosciences, a biotechnology company, were in focus today after brokerage firm Citi initiated coverage on the stock with a “Buy” recommendation. The brokerage has projected an upside potential of 17 per cent from the current market price.
As of 10:50 AM, the company’s shares were trading at Rs 744.20, up 2.8 per cent or Rs 20.5. Earlier in the session, the stock touched an intraday high of Rs 768.15, marking a gain of 6.1 per cent from its previous close of Rs 723.70.
Citi has expressed a positive outlook on the stock, citing strong growth prospects and multiple supporting factors that could drive future performance.
Citi has initiated coverage on Anthem Biosciences with a “Buy” rating and a target price of Rs 870, implying an upside of 16.9 per cent from the current market price.
According to Citi, the company is one of India’s fastest-growing CRDMOs, supported by a solid portfolio of commercial molecules and long-standing client relationships.
The company’s multi-modality platform and large-scale manufacturing capabilities position it well to capture rising demand in the pharmaceutical outsourcing space.
Anthem derives the highest share of revenue from commercial products among Indian peers, which enhances stability. Revenue is expected to grow at a CAGR of 26 per cent between FY23 and FY26, with Citi forecasting 15–16 per cent growth in FY26 alone. Looking further ahead, revenue and EBITDA are projected to grow at a CAGR of 19 per cent and 22 per cent, respectively, over FY26–FY28.
Growth drivers include a recovery in volumes of key products, momentum in legacy molecules, and the commercialisation of new molecules starting FY26.
Additional upside is expected from traction in products like Semaglutide and Peg-Fil. Margin expansion of 150–200 basis points is anticipated over the medium term, driven by backward integration and operating leverage, reinforcing the company’s positive outlook.
Mutual fund exposure in Anthem Biosciences
Mutual fund exposure to the company has seen a notable increase in recent months. According to the latest data available on the BSE, mutual fund holdings have risen to 10.2 per cent, up from 6.9 per cent earlier.
This growing institutional interest is led by funds such as Quant Mutual Fund’s Quant Mid Cap Fund, HDFC Mutual Fund’s HDFC Nifty Midcap 150 ETF, and SBI Nifty Midcap 150 Index Fund, reflecting increased confidence among domestic institutional investors in the company’s prospects.
(Disclaimer: The above article is meant for informational purposes only, and should not be considered as any investment advice. ET NOW DIGITAL suggests its readers/audience to consult their financial advisors before making any money-related decisions.)
